The global bipolar disorder treatment market is anticipated to grow at a considerable CAGR of 2.6% during the forecast period (2023-2030). Increasing R&D activities for the treatment of bipolar disorder treatment and acute treatment of manic or mixed market growth over the forecast period. For instance, in December 2021 Intra-Cellular Therapies, Inc. announced that US Food and Drug Administration (FDA) has approved Caplyta (lumateperone) for the treatment of bipolar depression in adults. Caplyta, is the only drug approved by the FDA for the treatment of depressive episodes stemming from bipolar I or bipolar II disorder in adults as monotherapy or adjunctive therapy with either valproate or lithium. According to WHO, in 2019, 40 million people experienced bipolar disorder. People with bipolar disorder experience alternating depressive episodes with periods of manic symptoms. During a depressive episode, the person experiences depressed mood or a loss of pleasure or interest in activities, for most of the day, nearly every day. As per WHO, in 2019, 280 million people were living with depression, including 23 million children and adolescents.
Browse the full report description of “Bipolar Disorder Treatment Market Size, Share & Trends Analysis Report by Drug Class (Mood stabilizer, Anticonvulsant, Antipsychotic Drug, Antidepressant Drug, and Other), and by Distribution Channel (Hospitals and Clinics, Retail Pharmacies, and Online Pharmacies) Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/bipolar-disorder-treatment-market
The current pharmaceutical treatments for bipolar disorder are inadequate with burdensome side-effects, unclear mechanisms of actions and limited efficacy. Since it does not address the mood instability that is characteristic of the illness, repurposing medications used for other psychiatric conditions has been the main source of incremental advances in bipolar disorder drug development. This approach has failed to produce truly revolutionary therapies. But CaMKK2 as an emerging treatment target for bipolar disorder. A compelling new treatment target is the Ca2+-calmodulin dependent protein kinase kinase-2 (CaMKK2) enzyme. CaMKK2 is highly enriched in brain neurons and regulates energy metabolism and neuronal processes that underpin higher order functions such as long-term memory, mood, and other affective functions. Bipolar disease has been linked to loss-of-function polymorphisms and an uncommon missense mutation in human CAMKK2, and animals with genetic deletions of Camkk2 exhibit behavior resembling those of bipolar patients. Moreover, lithium, which raises CaMKK2 activity, improves these behaviors. Given the large clinical, social and economic burden of bipolar disorder, the development of better treatment options is an urgent priority.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Drug Class
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes AbbVie Inc., Pfizer Inc., AstraZeneca, Abbott, Eli Lilly and Compnay, and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Bipolar Disorder Treatment Market Report Segment
By Drug Class
By Distribution Channel
Global Bipolar Disorder Treatment Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/bipolar-disorder-treatment-market